Blvr Valves denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for blvr valves are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Bronchoscopic Lung Volume Reduction Valves as "Duplicate Therapy"

Bronchoscopic lung volume reduction (BLVR) using endobronchial valves is a bronchoscopic intervention for severe emphysema. A "duplicate therapy" denial from Humana in this context typically arises when the plan's system identifies that the patient is already receiving another lung-volume reduction strategy — most often surgical lung volume reduction surgery (LVRS) has been coded in the patient's history, or a prior BLVR procedure was performed within a period that Humana's policy treats as precluding a repeat. Less commonly, the denial reflects a claim-processing error that conflated a diagnostic bronchoscopy with a therapeutic BLVR procedure.

This denial type is often appealable because BLVR valves and surgical LVRS are categorically different procedures with different risk profiles, eligibility criteria, and clinical indications. A patient who received one does not automatically duplicate the other.

## Your Federal Appeal Rights

ACA §2719 and ERISA §503 guarantee internal appeal and, if that fails, binding external review by an Independent Review Organization (IRO). You have up to 180 days from the denial notice to file an internal appeal, and generally four months after the final internal denial to request IRO review. Expedited review applies when delay would seriously jeopardize health — relevant for patients with severe emphysema who are clinically deteriorating.

## Documentation to Gather

• Procedure history clarification: A letter from the treating pulmonologist or thoracic surgeon distinguishing the proposed BLVR valve procedure from any prior lung-volume reduction intervention in the patient's record — including exact procedure dates, CPT codes, and clinical context for each.
• Prior-authorization or claim records: Copies of any prior Humana authorizations or claims for lung-related procedures to identify what triggered the duplicate flag.
• Current clinical status: Chart notes documenting current pulmonary function, exercise tolerance, and quality-of-life impact — demonstrating that a new or continued intervention is clinically warranted and not a redundant repetition.
• Applicable guideline reference: A prescriber citation to the relevant professional society guideline (e.g., applicable ATS/ERS/CHEST emphysema management guideline) that distinguishes bronchoscopic and surgical volume reduction as distinct modalities.

## Criteria-Mapping Structure

Address the duplicate-therapy finding directly: list what Humana identified as the "duplicate," then provide a side-by-side comparison showing how the proposed procedure differs in mechanism, indication, and clinical purpose. Attach supporting chart documentation for each row.